Survival of Patients With Cancer With DPYD Variant Alleles and Dose-Individualized Fluoropyrimidine Therapy-A Matched-Pair Analysis.

doi:10.1200/JCO.22.02780

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Survival of Patients With Cancer With DPYD Variant Alleles and Dose-Individualized Fluoropyrimidine Therapy-A Matched-Pair Analysis.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 10 Dec 2023

Knikman Jonathan E, Wilting Tycho A, Lopez-Yurda Marta, Henricks Linda M, Lunenburg Carin A T C, de Man Femke M, Meulendijks Didier, Nieboer Peter, Droogendijk Helga J, Creemers Geert-Jan, Mandigers Caroline M P W, Imholz Alexander L T, Mathijssen Ron H J, Portielje Johanneke E A, Valkenburg-van Iersel Liselot, Vulink Annelie, van der Poel Marlene H W, Baars Arnold, Swen Jesse J, Gelderblom Hans, Schellens Jan H M, Beijnen Jos H, Guchelaar Henk-Jan, Cats Annemieke

Abstract excerpt

PURPOSE: DPYD-guided fluoropyrimidine dosing improves patient safety in carriers of DPYD variant alleles. However, the impact on treatment outcome in these patients is largely unknown. Therefore, progression-free survival (PFS) and overall survival (OS) were compared between DPYD variant carriers treated with a reduced dose and DPYD wild-type controls receiving a full fluoropyrimidine dose in a retrospective...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alleles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cancer Treatment and Pharmacology

Share to Capecitabine

Share to Dihydrouracil Dehydrogenase (NADP)

Share to Fluorouracil

Share to Genotype

Share to Matched-Pair Analysis

Share to Neoplasms

Source

Open in PubMed

Identifiers

PMID: 37639651
DOI: 10.1200/JCO.22.02780

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Survival of Patients With Cancer With DPYD Variant Alleles and Dose-Individualized Fluoropyrimidine Therapy-A Matched-Pair Analysis.PMID 37639651Read ↗

Effectiveness and safety of reduced‐dose fluoropyrimidine therapy in patients carrying the DPYD*2A variant: A matched pair analysisSemantic proximity Read ↗

Optimizing fluoropyrimidine therapy: Real‐world impact of DPYD genotype‐based dosing on severe toxicity ratesSemantic proximity Read ↗

Real‐world study on fluoropyrimidine‐related toxicity outcomes in cancer patients with select DPYD variant alleles that received DPYD genotype‐guided dosingSemantic proximity Read ↗

Novel Genetic Variants Explaining Severe Adverse Drug Events after Clinical Implementation of DPYD Genotype-Guided Therapy with FluoropyrimidinesSemantic proximity Read ↗

Impact of pharmacogenomic DPYD variant guided dosing on toxicity in patients receiving fluoropyrimidines for gastrointestinal cancers in a high-volume tertiary centre.Semantic proximity Read ↗

Tailored treatment and clinical management for DPYD compound heterozygous: a multidisciplinary teamworkSemantic proximity Read ↗

Patients carrying DPYD variant alleles have increased risk of severe toxicity and related treatment modifications during fluoropyrimidine chemotherapy.Semantic proximity Read ↗

Discovering novel germline genetic variants linked to severe fluoropyrimidine-related toxicity in- and outside DPYD.Semantic proximity Read ↗

Response to the FDA Decision Regarding DPYD Testing Prior to Fluoropyrimidine Chemotherapy.Semantic proximity Read ↗

A predictive model for life-threatening fluoropyrimidine toxicity based on DPYD sequencing in colorectal cancer.Semantic proximity Read ↗

Clinical Implementation of Rare and Novel DPYD Variants for Personalizing Fluoropyrimidine Treatment: Challenges and OpportunitiesSemantic proximity Read ↗

Identification of Additional DPYD Polymorphisms That Increase the Risk of Severe Fluoropyrimidine Toxicity and Improve Predictive Accuracy when Combined with Previously Validated Variants.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.